Lumicell Stock

lumicell.comHealthcareFounded: 2009Funding to Date: $54.34MM

Lumicell is a provider image-guided cancer surgery, offering technology that illuminates cancer cells in the tumor cavity, enabling physicians to take action in real time to improve patient outcomes.

Register for Details

For more details on financing and valuation for Lumicell, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Lumicell.

Register Today

Team

Management Team

Kelly Londy
Chief Executive Officer & Operational Executive, Board of Directors
Felix Geissler
Chief Medical Officer
Kevin Hershberger
Chief Financial Officer
David Strasfeld Ph.D
Director, Research & Development
W. David Lee
Co-Founder, President, Chief Scientific Officer & Board Member
Jorge Ferrer Ph.D
Senior Vice President, Research & Development

Board Members

Andrey Zarur Ph.D
Kodiak Venture Partners
Kelly Londy
Moungi Bawendi Ph.D
Jim Schuermann
Michael Ruettgers
Ralph Weissleder Ph.D
David Furneaux
Kevin Krenitsky MD
W. David Lee

Other companies like Lumicell in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$298.33MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$327.39MM
Sector
 
 
Sector
Last Round Est. Valuation
$500MM

News

Lumicell, Inc., a Wellesley, Mass.-based technology leader in the field of image-guided cancer surgery, raised $28.7M in Series C financing. Backers included Launch Capital and BlueIO. The company intends to use the funds to continue to develop its LUM system pipeline including plans to initiate its pivotal trial in breast cancer as well as expansion …
Lumicell has raised $20.7 million over the past three months, according to a regulatory document filed with SEC last week. More than 20 investors have contributed to the $26.5 million equity offering, the Wellesley, Mass.-based company reported, including one investor outside of the U.S. Get the full story at our sister site, Drug Delivery Business News.